
Radium relaunches under Oslo Cancer Cluster
Oslo Cancer Cluster takes over the podcast Radium, expanding its focus on innovation, collaboration and the people driving change in the cancer field.

Oslo Cancer Cluster takes over the podcast Radium, expanding its focus on innovation, collaboration and the people driving change in the cancer field.

Andre utflukt for de 19 elevene som tar Medisinsk Innovasjon som fordypning i første klasse ved Ullern videregående skole, gikk til Radiumhospitalet for å lære mer om protonbehandling. Det ble et inspirerende besøk for både elevene og omviser Jonas Asperud, som er medisinsk fysiker ved senteret.

Ketil Widerberg slutter i Oslo Cancer Cluster etter 12 år som leder av Norges eldste helseklynge.

New funding will help Oncoinvent advance its ovarian cancer programme and prepare for Phase III development.

Oslo Cancer Cluster takes a key role in a major European initiative that aims to strengthen cancer collaboration across countries and connect partners beyond the EU.

A new science specialisation at Ullern Upper Secondary School will give students first-hand experience of medical research and innovation.
Get monthly news updates and invitations to events from our oncology cluster.

From Tehran to Oslo, how one researcher is developing a new weapon against treatment-resistant cancers.

With offices in Norway, Sweden and Denmark, NordicRWE wants to strengthen collaboration on health data and cancer innovation.

A Centre of Excellence for personalised training before, during and after cancer has been established in Oslo Cancer Cluster Innovation Park.

Under Arendalsuka satte vi søkelyset på noen av de viktigste spørsmålene innen kreftforskning, innovasjon og helsepolitikk. Her kan du se samtalene i opptak.

Eksperter og politikere mente at klarere økonomiske insentiver til sykehusene er det viktigste tiltaket for å få flere kliniske studier til Norge.

Six new members have joined the board of Oslo Cancer Cluster, highlighting the need for more international collaboration, better framework conditions for innovation and commercialisation, and improved patient access.

